# Fed Bioequivalence Study of CBZ Formulations

> **NCT02132897** · PHASE1 · COMPLETED · sponsor: **Center for Clinical Pharmacology Research Bdbeq S.A.** · enrollment: 20 (actual)

## Conditions studied

- Bio-equivalence Study
- Fed Conditions

## Interventions

- **DRUG:** Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
- **DRUG:** Tegretol CR 400 Single Dose-Auration CR 400 Single Dose

## Key facts

- **NCT ID:** NCT02132897
- **Lead sponsor:** Center for Clinical Pharmacology Research Bdbeq S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132897, "Fed Bioequivalence Study of CBZ Formulations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02132897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*